



## PRIDE-HD

### Why is this study being done?

Huntington disease is associated with three types of symptoms: motor, behavioral, and cognitive.

Dopamine is a chemical is important for several aspects of brain function including motor. Currently there is not a drug that manages all the different types of motor symptoms. This study is to test a new drug to see:

- If it is helpful to people with HD

### What is the drug being studied?

Pridopidine (TV-7820, formerly known as ACR16) is from a group of drugs which are believed to stabilize dopamine. There is evidence that the functioning of dopamine in the brain is a problem in HD.

### How can you help?

If you have been diagnosed with HD, ask to speak to a member of the research team. We can explain the study, including benefits and risks. We will also talk to you to determine if the study is a good fit for you.

### What is required if you participate?

- You and your caregiver will be asked to sign a consent form
- You and your caregiver will be required to participate in 10 in-person visits to complete
  - a physical examination
  - surveys/questionnaires
  - thinking tests
- You will have to provide blood and urine samples
- Take the study medication (or a placebo) as prescribed for 26 weeks.

### Want more information or want to participate?

More information can be found at [clinicaltrials.gov](http://clinicaltrials.gov). You can also ask to speak to a member of the research team or contact

Ginger Norris, MGC, CGC  
Research Manager  
Phone: (804) 662-5307  
email: [vwnorris@vcu.edu](mailto:vwnorris@vcu.edu)

**OR**

Claudia Testa, MD, PhD  
Neurologist/Principal Investigator  
Phone: (804) 662-5300  
email: [ctesta@vcu.edu](mailto:ctesta@vcu.edu)